Literature DB >> 29895666

Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective.

Kieron Dunleavy1, Thomas G Gross2.   

Abstract

The adolescents and young adult (AYA) population represent a group wherein mature B-cell lymphomas constitute a significant proportion of the overall malignancies that occur. Among these are aggressive B-cell non-Hodgkin lymphomas (NHLs), which are predominantly diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and Burkitt lymphoma. For the most part, there is remarkable divide in how pediatric/adolescent patients (under the age of 18 years) with lymphoma are treated vs their young adult counterparts, and molecular data are lacking, especially in pediatric and AYA series. The outcome for AYA patients with cancers has historically been inferior to that of children or older adults, highlighting the necessity to focus on this population. This review discusses the pediatric vs adult perspective in terms of how these diseases are understood and approached and emphasizes the importance of collaborative efforts in both developing consensus for treatment of this population and planning future research endeavors.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 29895666      PMCID: PMC6071562          DOI: 10.1182/blood-2018-02-778480

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

Authors:  Georg Lenz; R Eric Davis; Vu N Ngo; Lloyd Lam; Thaddeus C George; George W Wright; Sandeep S Dave; Hong Zhao; Weihong Xu; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Wing C Chan; Louis M Staudt
Journal:  Science       Date:  2008-03-06       Impact factor: 47.728

2.  The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age.

Authors:  Sylvain Mareschal; Hélène Lanic; Philippe Ruminy; Christian Bastard; Hervé Tilly; Fabrice Jardin
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

3.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

Review 4.  Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes.

Authors:  Justine M Kahn; Nmazuo W Ozuah; Kieron Dunleavy; Tara O Henderson; Kara Kelly; Ann LaCasce
Journal:  Blood Adv       Date:  2017-10-10

5.  Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

Authors:  James N Kochenderfer; Robert P T Somerville; Tangying Lu; Victoria Shi; Adrian Bot; John Rossi; Allen Xue; Stephanie L Goff; James C Yang; Richard M Sherry; Christopher A Klebanoff; Udai S Kammula; Marika Sherman; Arianne Perez; Constance M Yuan; Tatyana Feldman; Jonathan W Friedberg; Mark J Roschewski; Steven A Feldman; Lori McIntyre; Mary Ann Toomey; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

Review 6.  Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.

Authors:  Rodney R Miles; Rikin K Shah; J Kimble Frazer
Journal:  Br J Haematol       Date:  2016-03-11       Impact factor: 6.998

7.  Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents.

Authors:  Monika Szczepanowski; Jonas Lange; Christian W Kohler; Neus Masque-Soler; Martin Zimmermann; Sietse M Aukema; Michael Altenbuchinger; Thorsten Rehberg; Friederike Mahn; Reiner Siebert; Rainer Spang; Birgit Burkhardt; Wolfram Klapper
Journal:  Br J Haematol       Date:  2017-06-23       Impact factor: 6.998

8.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

9.  A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

Authors:  Graham M Mead; Sharon L Barrans; Wendi Qian; Jan Walewski; John A Radford; Max Wolf; Simon M Clawson; Sally P Stenning; Claire L Yule; Andrew S Jack
Journal:  Blood       Date:  2008-07-08       Impact factor: 22.113

10.  Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.

Authors:  S Goldman; L Smith; J R Anderson; S Perkins; L Harrison; M B Geyer; T G Gross; H Weinstein; S Bergeron; B Shiramizu; W Sanger; M Barth; J Zhi; M S Cairo
Journal:  Leukemia       Date:  2012-09-03       Impact factor: 11.528

View more
  7 in total

1.  Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.

Authors:  Joan Enric Ramis-Zaldivar; Blanca Gonzalez-Farré; Olga Balagué; Verónica Celis; Ferran Nadeu; Julia Salmerón-Villalobos; Mara Andrés; Idoia Martin-Guerrero; Marta Garrido-Pontnou; Ayman Gaafar; Mariona Suñol; Carmen Bárcena; Federico Garcia-Bragado; Maitane Andión; Daniel Azorín; Itziar Astigarraga; Maria Sagaseta de Ilurdoz; Constantino Sábado; Soledad Gallego; Jaime Verdú-Amorós; Rafael Fernandez-Delgado; Vanesa Perez; Gustavo Tapia; Anna Mozos; Montserrat Torrent; Palma Solano-Páez; Alfredo Rivas-Delgado; Ivan Dlouhy; Guillem Clot; Anna Enjuanes; Armando López-Guillermo; Pallavi Galera; Matthew J Oberley; Alanna Maguire; Colleen Ramsower; Lisa M Rimsza; Leticia Quintanilla-Martinez; Elaine S Jaffe; Elías Campo; Itziar Salaverria
Journal:  Blood       Date:  2020-01-23       Impact factor: 22.113

Review 2.  Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Authors:  Irtiza N Sheikh; Amr Elgehiny; Dristhi Ragoonanan; Kris M Mahadeo; Yago Nieto; Sajad Khazal
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

3.  Continuous infusion chemotherapy, radiotherapy, and FDG-PET are feasible during extracorporeal membrane oxygenation.

Authors:  Seth J Rotz; Francisco A Almeida; Shlomo Koyfman; Sudhir Krishnan; Guramrinder Singh Thind; William Phillips; James Yun; Anthony Zembillas; Mark Zahniser; Alejandro Bribriesco
Journal:  Pediatr Blood Cancer       Date:  2020-07-16       Impact factor: 3.167

4.  Optimizing outcomes in primary mediastinal B-cell lymphoma: is R-CHOP enough?

Authors:  Michael R Cook; Kieron Dunleavy
Journal:  Blood Adv       Date:  2021-10-12

5.  Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.

Authors:  Blanca Gonzalez-Farre; Joan Enric Ramis-Zaldivar; Julia Salmeron-Villalobos; Olga Balagué; Verónica Celis; Jaime Verdu-Amoros; Ferran Nadeu; Constantino Sábado; Antonio Ferrández; Marta Garrido; Federico García-Bragado; María Dolores de la Maya; José Manuel Vagace; Carlos Manuel Panizo; Itziar Astigarraga; Mara Andrés; Elaine S Jaffe; Elias Campo; Itziar Salaverria
Journal:  Haematologica       Date:  2019-02-07       Impact factor: 9.941

Review 6.  Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma.

Authors:  Murali Kesavan; Toby A Eyre; Graham P Collins
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

Review 7.  Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.

Authors:  Coen J Lap; Samah Nassereddine; Kieron Dunleavy
Journal:  Curr Treat Options Oncol       Date:  2021-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.